{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:03:18Z","timestamp":1786636998227,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Endocr Metab"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/2230-8210.95661","type":"journal-article","created":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T08:59:51Z","timestamp":1336208391000},"page":"343","source":"Crossref","is-referenced-by-count":32,"title":["Teriparatide - Indications beyond osteoporosis"],"prefix":"10.4103","volume":"16","author":[{"given":"Vishal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MarilynLee","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2230-8210.95661-1","first-page":"1","article-title":"Osteoporosis prevention, diagnosis and therapy","author":"National","year":"2000","journal-title":"NIH Consens Statement"},{"key":"key-10.4103\/2230-8210.95661-2","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.2165\/0003495-200868180-00012","article-title":"Teriparatide : A0 review of its use in osteoporosis","author":"Blick","year":"2008","journal-title":"Drugs"},{"key":"key-10.4103\/2230-8210.95661-3","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.Report of a WHO Study Group","author":"WHO","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"key":"key-10.4103\/2230-8210.95661-4","unstructured":"US FDA; Teriparatide (rDNA origin) injection 750 mcg\/3 ml. Available from : 0 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021318s015lbl.pdf. [Last accessed on 2011 Nov 13]."},{"key":"key-10.4103\/2230-8210.95661-5","first-page":"447","article-title":"Parathyroid hormone (1-84) and teriparatide in the treatment of postmenopausal osteoporosis","author":"Bogado","year":"2006","journal-title":"Womens Health"},{"key":"key-10.4103\/2230-8210.95661-6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11154-006-9007-z","article-title":"The use of parathyroid hormone in the treatment of osteoporosis","author":"Girotra","year":"2006","journal-title":"Rev Endocr Metab Disord"},{"key":"key-10.4103\/2230-8210.95661-7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1210\/jcem.86.3.7366","article-title":"Anabolic therapy for osteoporosis","author":"Rosen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis : A0 review of the evidence and suggested guidelines for its use","author":"Hodsman","year":"2005","journal-title":"Endocrine Rev"},{"key":"key-10.4103\/2230-8210.95661-9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.95661-10","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.2165\/00003495-200666180-00008","article-title":"Recombinant full-length parathyroid hormone (1-84)","author":"Moen","year":"2006","journal-title":"Drugs"},{"key":"key-10.4103\/2230-8210.95661-11","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1210\/jc.2003-030768","article-title":"Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis","author":"Hodsman","year":"2003","journal-title":"J Clin Endocrinol Metabol"},{"key":"key-10.4103\/2230-8210.95661-12","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1210\/endo.136.11.7588200","article-title":"Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84)","author":"Inomata","year":"1995","journal-title":"Endocrinology"},{"key":"key-10.4103\/2230-8210.95661-13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1210\/endo.142.2.7955","article-title":"Receptors for the carboxyl-terminal region of PTH (1- 84) are highly expressed in osteocytic cells","author":"Divieti","year":"2001","journal-title":"Endocrinology"},{"key":"key-10.4103\/2230-8210.95661-14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1073\/pnas.71.2.384","article-title":"The amino acid sequence of the amino-terminal 37 residues of human parathyroid hormone","author":"Niall","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2230-8210.95661-15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.beem.2008.06.003","article-title":"Bone-forming agents in the management of osteoporosis","author":"Neuprez","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1517\/14712598.2010.506870","article-title":"PTH analogues and osteoporotic fractures","author":"Verhaar","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"key-10.4103\/2230-8210.95661-17","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","author":"Chen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-18","first-page":"415","article-title":"The anabolic effects of parathyroid hormone therapy","author":"Rubin","year":"2002","journal-title":"Clin Geriat Med"},{"key":"key-10.4103\/2230-8210.95661-19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1359\/jbmr.2001.16.1.157","article-title":"Intermittently administered human parathyroidhormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys","author":"Burr","year":"2001","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-21","unstructured":"Available from : 0 http:\/\/pi.lilly.com\/us\/forteo-pi.pdf. [Last accessed on 2011 Nov 13]."},{"key":"key-10.4103\/2230-8210.95661-22","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/2230-8210.95661-23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.95661-24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1185\/030079906X104768","article-title":"A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis : A0 6-month study","author":"Kung","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2230-8210.95661-26","first-page":"101ra93","article-title":"Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis","author":"Sampson","year":"2011","journal-title":"Sci Transl Med"},{"key":"key-10.4103\/2230-8210.95661-27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jcb.10435","article-title":"Fracture healing as a post-natal develop- mental process : M0 olecular, spatial and temporal aspects of its regulation","author":"Gerstenfeld","year":"2003","journal-title":"J Cell Biochem"},{"key":"key-10.4103\/2230-8210.95661-28","first-page":"121","article-title":"Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model","author":"O\u2032Loughlin","year":"1976","journal-title":"Spine (Phila Pa"},{"key":"key-10.4103\/2230-8210.95661-29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1359\/jbmr.070724","article-title":"Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures","author":"Kakar","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-30","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1210\/jc.2010-2520","article-title":"Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy","author":"Gomberg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-31","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1210\/jc.2010-1168","article-title":"Parathyroid hormone treatment improves pain and fracture healing in adult hypophosphatasia","author":"Schalin-J\u00e4ntti","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/17453671003761946","article-title":"Teriparatide improves early callus formation in distal radial fractures","author":"Aspenberg","year":"2010","journal-title":"Acta Orthop"},{"key":"key-10.4103\/2230-8210.95661-33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/BSD.0b013e31819a8b7a","article-title":"Teriparatide may accelerate healing in delayed unions of type III odontoid fractures : A0 report of 3 cases","author":"Rubery","year":"2010","journal-title":"J Spinal Disord Tech"},{"key":"key-10.4103\/2230-8210.95661-34","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00198-009-1061-4","article-title":"Successful treatment of sternal fracture nonunion with teriparatide","author":"Chintamaneni","year":"2010","journal-title":"Osteoporosis Int"},{"key":"key-10.4103\/2230-8210.95661-35","doi-asserted-by":"crossref","first-page":"0 e22","DOI":"10.1016\/j.jse.2010.05.005","article-title":"Atrophic humeral shaft nonunion treated with teriparatide (rh PTH 1-34) : A0 case report","author":"Oteo-Alvaro","year":"2010","journal-title":"J Shoulder Elbow Surg"},{"key":"key-10.4103\/2230-8210.95661-36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","article-title":"Teriparatide for acceleration of fracture repair in humans : A0 prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures","author":"Aspenberg","year":"2010","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-37","unstructured":"Eli L. Forteo, teriparatide (rDNA)injection 750 mgs\/3 (online). Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm085729.htm. [Last accessed on 2011 Nov 13]."},{"key":"key-10.4103\/2230-8210.95661-38","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs.calcitriol and calcium in the treatment of hypoparathyroidism : R0 esults of a randomized crossover trial","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"key-10.4103\/2230-8210.95661-39","first-page":"3480","article-title":"A randomized, crossover trial of once daily vs.twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-40","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/EJE-08-0269","article-title":"Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide","author":"Puig-Domingo","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"key-10.4103\/2230-8210.95661-41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/TP.0b013e3182247b98","article-title":"Teriparatide efficacy in the treatment of severe hypocalcemia after kidney transplantation in parathyroidectomized patients : A0 series of five case reports","author":"Nogueira","year":"2011","journal-title":"Transplantation"},{"key":"key-10.4103\/2230-8210.95661-42","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism : A0 randomized controlled study comparing parathyroid hormone- (1-34) versus calcitriol and calcium","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-43","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism : A0 randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2230-8210.95661-44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4158\/EP10247.OR","article-title":"An 18 month open-label trial of teriparatide in patients with previous parathyroidectomy at continued risk for osteoporotic fractures : A0 n exploratory study","author":"Horowitz","year":"2011","journal-title":"Endocr Pract"},{"key":"key-10.4103\/2230-8210.95661-45","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","author":"Bashutski","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2230-8210.95661-46","doi-asserted-by":"crossref","first-page":"0 e337","DOI":"10.1016\/j.ajodo.2009.08.030","article-title":"Effect of teriparatide on induced tooth displacement in ovariectomized rats : A0 histomorphometric analysis","author":"Salazar","year":"2011","journal-title":"Am J Orthod Dentofacial Orthop"},{"key":"key-10.4103\/2230-8210.95661-47","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1601-0825.2011.01850.x","article-title":"Parathyroid hormone and its effects on dental tissues","author":"Aggarwal","year":"2012","journal-title":"Oral Dis"},{"key":"key-10.4103\/2230-8210.95661-48","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/j.1532-5415.2011.03713.x","article-title":"Bisphosphonates and osteonecrosis of the Jaw","author":"Shannon","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"key-10.4103\/2230-8210.95661-49","first-page":"9","article-title":"Study investigates novel approach to bone loss in the jaw","author":"Garg","year":"2011","journal-title":"Dent Implantol Update"},{"key":"key-10.4103\/2230-8210.95661-50","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate associated osteonecrosis of the jaw : R0 eport of a task force of the American Society for Bone and Mineral Research","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","article-title":"Bisphosphonates : M0 echanisms of action","author":"Fleisch","year":"1998","journal-title":"Endocr Rev"},{"key":"key-10.4103\/2230-8210.95661-52","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review : B0 isphosphonates and osteonecrosis of the jaws","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/2230-8210.95661-53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","article-title":"Resolution of bisphosphonate-associated osteonecrosis of the mandible : P0 ossible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]","author":"Harper","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"key-10.4103\/2230-8210.95661-54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1754-4505.2009.00128.x","article-title":"Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide : A0 review of the literature and a case report","author":"Narongroeknawin","year":"2010","journal-title":"Spec Care Dentist"},{"key":"key-10.4103\/2230-8210.95661-55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00198-010-1222-5","article-title":"Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis","author":"Lasco","year":"2011","journal-title":"Osteoporosis Int"},{"key":"key-10.4103\/2230-8210.95661-56","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis : A0 review of the evidence and suggested guidelines for its use","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"key-10.4103\/2230-8210.95661-57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","author":"Harper","year":"2007","journal-title":"J Bone Miner Res"},{"key":"key-10.4103\/2230-8210.95661-58","unstructured":"Surveillance Research Program. National Cancer Institute SEER_Stat Software; 2008."},{"key":"key-10.4103\/2230-8210.95661-59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections o recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:04:28Z","timestamp":1786633468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2230-8210.95661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"alternative-id":["95661"],"URL":"https:\/\/doi.org\/10.4103\/2230-8210.95661","relation":{},"ISSN":["2230-8210"],"issn-type":[{"value":"2230-8210","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}